Consumer medicine information

Cyclogyl

Cyclopentolate hydrochloride

BRAND INFORMATION

Brand name

Cyclogyl

Active ingredient

Cyclopentolate hydrochloride

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Cyclogyl.

What is in this leaflet

Read this leaflet carefully before you start to use Cyclogyl Eye Drops.

This leaflet answers some common questions about Cyclogyl Eye Drops. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

The information in this leaflet was last updated on the date listed on the final page. More recent information on the medicine may be available.

You should ensure that you speak to your pharmacist or doctor to obtain the most up to date information on the medicine.

You can also download the most up to date leaflet from
TGA eBusiness Services

The updates may contain important information about the medicine and its use of which you should be aware.

All medicines have risks and benefits. Your doctor has weighed the risks of you using Cyclogyl against the benefits they expect it will have for you.

The information in this leaflet applies to Cyclogyl Eye Drops only. This information does not apply to similar products, even if they contain the same ingredients.

If you have any concerns about using this medicine, ask your doctor or pharmacist.

Keep this leaflet with your medicine. You may need to read it again.

What Cyclogyl is used for

Cyclogyl Eye Drops are used to enlarge (dilate) the pupil and to prevent the eye from focussing. Your doctor may use Cyclogyl Eye Drops prior to a surgical procedure or prior to examining the inside of your eye.

Cyclogyl Eye Drops may also be used to relax the muscles of your eye. This may be necessary when some parts of the eye are inflamed (iridocyclitis).

How Cyclogyl works

Cyclogyl Eye Drops contain the active ingredient cyclopentolate hydrochloride which belongs to a class of medicines known as cycloplegics / mydriatics.

The effect of Cyclogyl Eye Drops is usually no longer than 24 hours.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another reason.

This medicine is not addictive.

This medicine is only available with a doctor's prescription.

Use in Children

Cyclogyl Eye Drops 1.0% should not be used in small infants.

Concentrations greater than 0.5% are not recommended due to the risk of serious side effects.

Infants, small children, children with brain damage or spastic paralysis, Down's syndrome, epilepsy (fits) or fair-skinned, blue eyed children are susceptible to the effects of Cyclogyl Eye Drops.

Before you use Cyclogyl

When you must not use it

Do not use this medicine if you have an allergy to:

  • any medicine containing cyclopentolate hydrochloride
  • any of the ingredients that are listed under "Product Description" at the end of the leaflet.

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

Tell your doctor if you have or have had any of the following medical conditions:

  • angle-closure glaucoma.

Prior to using Cyclogyl Eye Drops your doctor may check your eyes to see if you may be prone to angle-closure glaucoma.

Do not use this medicine if the expiry date has passed, the packaging is torn or the safety seal around the closure and neck area is broken. If it has expired or is damaged, return it to your pharmacist for disposal.

Talk to your doctor if you are not sure if this medicine is right for you.

Before you are given this medicine

Tell your doctor if have any allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have had a severe reaction to a medicine called atropine.

Tell your doctor if you are pregnant or plan to become pregnant. Your doctor will discuss the possible risks and benefits of using Cyclogyl during pregnancy.

Tell your doctor if you are breastfeeding. Your doctor will discuss the possible risks and benefits of using Cyclogyl when you are breast-feeding.

Taking or using other medicines

Tell your doctor if you are taking any other medicines, including any that you get without a prescription from a pharmacy, supermarket or health food shop.

Some medicines and Cyclogyl may interfere with each other. These include:

  • Other medicines used to treatment glaucoma.
  • Amantadine (Symmetrel) used to treat Parkinson's disease or type-A influenza
  • Antihistamines used to treat allergies
  • Phenothiazine used to treat severe mental illnesses
  • Tricyclic antidepressants used to treat depression.

Your doctor and pharmacists have more information on medicines to be careful with or avoid.

How Cyclogyl is given

Follow all directions given to you by your doctor or pharmacist carefully.

They may differ from the information contained in this leaflet.

If you do not understand the instructions on the carton, ask your doctor or pharmacist for help.

How much to use

Your doctor will put the correct number of drops in your eye(s) before you have an operation or an examination.

If you have been prescribed Cyclogyl Eye Drops for use outside the doctor's surgery the usual adult dose is one drop in the eye(s) followed by a second drop 5 minutes later.

Do not put Cyclogyl Eye Drops into your eye(s) while you are wearing soft contact lenses.

You can put your contact lenses back into your eyes 15 minutes after you have used Cyclogyl Eye Drops.

The usual dose for a child is one drop in the eye(s) followed by a second drop 5 minutes later, if necessary.

Carefully watch your child for 30 minutes after the use of Cyclogyl Eye Drops.

Your child may be difficult to feed following the use of Cyclogyl Eye Drops. It is recommended that you do not feed your child for 4 hours following the use of Cyclogyl Eye Drops.

Do not use Cyclogyl Eye Drops more often than your doctor or pharmacist has told you.

How to use Cyclogyl

Follow these steps to use Cyclogyl Eye Drops:

  1. Wash your hands thoroughly.
  2. Immediately before using a bottle for the first time, break the safety seal around the neck area and throw the loose plastic ring away.
  3. Remove the cap from the bottle.
  4. Hold the bottle upside down in one hand between your thumb and middle finger (see Diagram 1).

  1. While tilting your head back, gently pull the lower eyelid of your eye down using the forefinger of your other hand.
  2. Place the dropper tip close to, but not touching, your lower eyelid and gently tap or press the base of the bottle with your forefinger to release one drop (see Diagrams 2 and 3).

  1. Close your eye gently without blinking and press on the inside corner of your eye with the pad of your index finger for two minutes.
  2. If necessary, repeat the above steps 1-7 for your other eye.
  3. Place the cap on the bottle and close it tightly.
  4. Wash your hands again. If you have been using Cyclogyl Eye Drops in a child’s eye(s), make sure that you wash the child's hands as well.

You may feel a slight burning sensation in the eye shortly after using Cyclogyl Eye Drops. If this persists, or is very uncomfortable, contact your doctor or pharmacist.

Do not touch the tip of the dropper to your eye or to any other surface. This will help to prevent the eye drops becoming dirty or contaminated.

If you forget to use Cyclogyl

If you forget to use Cyclogyl Eye Drops, you should put in the drops that you missed as soon as you remember and then go back to using them normally. If it is almost time for your next dose, skip the dose that you have missed and take your next dose when you are due to.

Never use a double dose to make up for the one that you missed.

If you are not sure what to do, contact your doctor or pharmacist.

If you use too much (overdose)

Immediately telephone your doctor or the Poisons Information Centre on 13 11 26 for advice, or go to Accident and Emergency at the nearest hospital if you, or anyone else, accidentally swallows Cyclogyl Eye Drops.

If you accidentally put too many drops in your eye(s), immediately rinse your eye(s) with warm water.

Symptoms of overdose may include:

  • flushed or dry skin, rash (may be present in children)
  • blurred vision
  • rapid and irregular pulse
  • fever
  • abdominal swelling in children
  • convulsions
  • hallucinations
  • loss of muscle coordination.

Symptoms of a severe overdose include:

  • mental and behavioural disturbances (e.g. hallucinations, seizures or fits, disorientation)
  • coma
  • circulation failures
  • breathlessness.

Symptoms of a severe overdose can result in death.

While you are using CYCLOGYL

Things you must do

Tell your doctor, dentist or pharmacist that you are using Cyclogyl Eye Drops before you start taking any other medicines.

If you become pregnant or decide to breastfeed while using Cyclogyl, tell your doctor immediately.

Make sure that you take appropriate steps to protect your eye(s) from light. Your eyes will be very sensitive to light while you are using this medicine.

Things you must not do

  • Do not let children handle Cyclogyl Eye Drops. If a child accidentally swallows any of the drops, read the instructions under "If you use too much (overdose)".
  • Do not stop using Cyclogyl Eye Drops without first asking your doctor.
    If you stop using Cyclogyl your condition may worsen.
  • Do not give this medicine to anyone else, even if they appear to have the same condition as you.
  • Do not put Cyclogyl Eye Drops into your eye(s) while you are wearing contact lenses.
    The preservative in Cyclogyl Eye Drops, benzalkonium chloride, may be deposited in contact lenses.

Things to be careful of

While your eye(s) are affected by Cyclogyl Eye Drops, you should not drive, operate machinery or engage in any other hazardous activities.

Side Effects

Tell your doctor as soon as possible if you do not feel well while you are using Cyclogel Eye Drops.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

Do not be alarmed by the following list of side effects. You may not experience any of them.

Most side effects from Cyclogyl Eye Drops occur in, or around, the eye.

These include:

  • Increased pressure in the eye
  • Burning and irritation
  • Sensitivity to light
  • Blurred vision
  • Redness and irritation of the eyelid
  • Dilation of the pupil (prolonged effect)
  • Eye pain.

The effect that Cyclogyl Eye Drops has on the eye(s) usually does not last longer than 24 hours. In some individuals, however, complete recovery may require several days.

Occasionally, some people notice unwanted effects in the rest of their body as a result of using Cyclogyl Eye Drops.

There is a greater chance of such side effects occurring if Cyclogyl Eye Drops are used in children.

Tell your doctor immediately or go to hospital if you notice any of the following:

  • Mental and behavioural disturbances (e.g. unsteady walk, failure to recognise people, difficulty expressing thoughts and speaking clearly, forgetfulness)
  • Restlessness
  • Hallucinations
  • Seizures (or fits)
  • Disorientation
  • Confusion
  • Agitation
  • Dizziness
  • Headache
  • Sleepiness
  • Fatigue
  • Breathlessness
  • Nausea
  • Vomiting
  • Constipation
  • Abdominal swelling (infants)
  • Dry mouth and nasal passages
  • Changes in posture
  • Lack of muscle coordination
  • Fever
  • Fast heart beat
  • Flushed skin
  • Difficulty passing urine.

Tell your doctor immediately and stop using Cyclogyl Eye Drops at the first sign of an allergy.

Signs of an allergic reaction include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

Tell your doctor or pharmacist if you notice anything that is making you feel unwell.

Other side effects not listed above may also occur in some people.

After using Cyclogyl

Storage

Keep your eye drops at 2° to 8°C.

Refrigerate. Do not freeze.

Do not leave Cyclogyl Eye Drops or other medicines in the car, bathroom, near a sink or a window sill. Heat and humidity can destroy some medicines.

Keep Cyclogyl Eye Drops where children cannot reach it. A locked cupboard at least one and a half metres above the ground is a good place to store medicines.

Disposal

Discard each bottle of Cyclogyl Eye Drops 4 weeks after it has been opened.

Write the date on the bottle label when it was opened to remind you when to discard the bottle.

If your doctor tells you to stop using this medicine or the expiry date has passed, ask your pharmacist what to do with any medicines that is left over.

Product Description

What it looks like

Cyclogyl Eye Drops is a sterile solution that comes in a 5 mL dropper bottle (DROP-TAINER™) with screw cap. The safety seal must be removed before use.

Ingredients

The active ingredient in Cyclogyl is cyclopentolate hydrochloride 1% (10 mg/mL).

Cyclcogyl also contain

  • benzalkonium chloride 0.1 mg/mL as preservative
  • boric acid
  • disodium edetate
  • potassium chloride
  • sodium carbonate and/or hydrochloric acid to adjust pH
  • purified water.

Supplier

Cylogyl is supplied in Australia by:

Alcon Laboratories (Australia) Pty Ltd
ABN 88 000 740 830
15 Talavera Road
Macquarie Park NSW 2113
Telephone: 1800 224 153

Australian registration number

AUST R No. 25273

Date of preparation

This leaflet was prepared in August 2020.

Internal reference: cyc200820c

Published by MIMS October 2020

BRAND INFORMATION

Brand name

Cyclogyl

Active ingredient

Cyclopentolate hydrochloride

Schedule

S4

 

1 Name of Medicine

Cyclopentolate hydrochloride.

2 Qualitative and Quantitative Composition

Cyclogyl eye drops contain cyclopentolate hydrochloride 10 mg/mL (1.0%).
It also contains benzalkonium chloride 0.1 mg/mL as a preservative.
For the full list of excipients see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Eye drops.
Cyclogyl eye drops have been formulated as a sterile, multi-dose product for topical ophthalmic use. The pH of Cyclogyl eye drops is approximately 4.5.

4 Clinical Particulars

4.1 Therapeutic Indications

For mydriasis and cycloplegia in diagnostic procedures. For some pre- and post-operative states when mydriasis is required and when a shorter acting mydriatic and cycloplegic is needed in the therapy of iridocyclitis.

4.2 Dose and Method of Administration

Adults.

One drop, followed by a second drop in 5 minutes.
Complete recovery usually occurs in 24 hours.

Children.

One drop is instilled in each eye, followed 5 minutes later by a second application if necessary.
Pretreatment with Cyclogyl eye drops on the day prior to examination usually is not necessary.
In order to minimise systemic absorption, apply pressure to the tear duct for two minutes immediately after administration.

4.3 Contraindications

Should not be used:
when narrow-angle glaucoma or anatomically narrow angles are present;
when there is hypersensitivity to any component of this preparation (see Section 6.1 List of Excipients).

4.4 Special Warnings and Precautions for Use

For ophthalmic use only - not for injection.
This preparation may cause psychotic reactions, behavioural disturbances and other CNS disturbances in patients with increased susceptibility to anticholinergic drugs. This is especially true in younger age groups, but may occur at any age. Premature and small infants are especially prone to CNS and cardiopulmonary side effects from systemic absorption of cyclopentolate and, therefore, Cyclogyl eye drops should not be used in these patients.
Use with caution in patients, especially children, who have previously had a severe systemic reaction to atropine.
Cyclogyl may cause increased intraocular pressure. The possibility of undiagnosed glaucoma should be considered in some patients, such as elderly patients. Caution should be observed when considering the use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma. To avoid inducing angle-closure glaucoma, determine the intraocular pressure and an estimation of the depth of the anterior chamber should be made prior to the initiation of therapy.
Complete recovery of accommodation usually occurs within 24 hours, however, in some individuals complete recovery may require several days.
Because of risk of provoking hyperthermia, use with caution in patients, especially children, who may be exposed to elevated environmental temperatures or who are febrile.

Use in hepatic impairment.

No formal studies have been conducted in patients with hepatic impairment.

Use in renal impairment.

No formal studies have been conducted in patients with renal impairment.

Use in the elderly.

In the elderly and others where increased intraocular pressure may be encountered, mydriatics and cycloplegics should be used with caution.
Elderly patients may be a higher risk for undiagnosed glaucoma as well as cyclopentolate induced psychotic reactions and behavioural disturbances.

Paediatric use.

Cyclogyl 1% eye drops should not be used in small infants as concentrations greater than 0.5% are not recommended due to the risk of serious systemic side effects (see Section 4.4 Special Warnings and Precautions for Use; Section 4.8 Adverse Effects (Undesirable Effects); Section 4.9 Overdose).
Increased susceptibility to cyclopentolate has been reported in infants, young children and in children with Down syndrome, spastic paralysis or brain damage to central nervous system disturbances, and cardiopulmonary and gastrointestinal toxicity from systemic absorption of cyclopentolate. Cyclopentolate should not, therefore, be used in premature and small infants and should be used with great caution in young children and in children with Down syndrome, spastic paralysis or brain damage.
Seizures and acute psychosis induced by cyclopentolate are especially prominent in children. Cyclopentolate should be used with caution in children, with known epilepsy.
Fair-skinned children with blue eyes may exhibit an increased response and/or increased susceptibility to adverse reactions.
Observe infants closely for at least 30 minutes following instillation.
Feeding intolerance and necrotising enterocolitis (NEC) in preterm infants may follow ophthalmic use of this product in infants. Cases of NEC have been reported in preterm infants following administration. It is recommended that feeding be withheld for 4 hours after examination in infants.
Parents should be warned not to get this preparation in their children's mouth or cheeks and to wash their hands and the child's hands or cheeks following administration.

Effects on laboratory tests.

No data available.

Information for patients.

Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.
Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration.
After cap is removed, if tamper evident snap collar is loose, remove before using product.
Do not touch the dropper tip to any surface as this may contaminate the solution.
A transient burning sensation may occur upon instillation.

Contact lenses.

Cyclogyl eye drops contain benzalkonium chloride which may cause eye irritation and is known to discolour soft contact lenses. Avoid contact with soft contact lenses. Patients must be instructed to remove contact lenses prior to application of Cyclogyl eye drops and wait 15 minutes before reinsertion.

4.5 Interactions with Other Medicines and Other Forms of Interactions

The effects of Cyclogyl eye drops may be enhanced by concomitant use of other drugs having antimuscarinic properties, such as amantadine, some antihistamines, phenothiazine antipsychotics, and tricyclic antidepressants. Cyclopentolate may interfere with the antiglaucoma action of carbachol or pilocarpine; also, concurrent use of this medication may antagonise the anti-glaucoma and miotic actions of ophthalmic cholinesterase inhibitors.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Studies have not been performed to evaluate the effects of topical ocular administration of cyclopentolate on fertility.
(Category B2)
Animal reproduction studies have not been conducted with cyclopentolate. It is not known whether cyclopentolate can cause foetal harm when administered to a pregnant woman or can affect reproductive capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. A risk to the suckling child cannot be excluded. Because many drugs are excreted in human milk, use only when considered essential by the physician.

4.7 Effects on Ability to Drive and Use Machines

Cyclopentolate eye drops may cause drowsiness and blurred vision. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated, unless vision is clear. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation.

4.8 Adverse Effects (Undesirable Effects)

Ocular.

Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperaemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae.

Systemic.

Use of cyclopentolate has been associated with psychotic reactions and behavioural disturbances in children. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognise people.
This drug produces reactions similar to those of other anticholinergic drugs, however, the central nervous system manifestations as noted above are more common. Other toxic manifestations of anticholinergic drugs are tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death.

Postmarketing events.

The following adverse reactions have been reported following administration of Cyclogyl eye drops. Frequency cannot be estimated from the available data. Within each system organ class, adverse reactions are presented in order of decreasing seriousness.

Eye disorders.

Not known: photophobia, drug effect prolonged (mydriasis), eye irritation, vision blurred, eye pain, ocular hyperaemia.

Nervous system disorders.

Not known: incoherent, retrograde amnesia, dizziness, headache, somnolence.

Psychiatric disorders.

Not known: hallucination, confusional state, disorientation, agitation, restlessness.

Immune system disorders.

Not known: hypersensitivity.

Gastrointestinal disorders.

Not known: vomiting, nausea, dry mouth.

Skin and subcutaneous tissue disorders.

Not known: erythema.

General disorders and administration site conditions.

Not known: gait disturbance, pyrexia, fatigue.

Description of selected adverse reactions.

This drug produces reactions similar to those of other anticholinergic drugs. The central nervous system manifestations such as ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people are possible. Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility, and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe reactions are manifested by hypotension with rapid progressive respiratory depression.
Cyclogyl eye drops may increase intraocular pressure and provoke glaucoma attacks in patients predisposed to acute angle closure in particular geriatric patients (see Section 4.4 Special Warnings and Precautions for Use).
The onset of cyclopentolate toxicity occurs within 20 to 30 minutes of drug instillation, and although usually transient (subsiding in 4 to 6 hours), the symptoms can last 12 to 24 hours.

Paediatric population.

Increased risk for systemic toxicity has been observed in premature and small infants, young children, or children with Down syndrome, spastic paralysis or brain damage with this class of drug (see Section 4.4 Special Warnings and Precautions for Use).
Use of Cyclogyl eye drops has been associated with psychotic reactions and behaviour changes in paediatric patients. Central nervous system reactions manifest similar to those listed above. Seizures and acute psychosis induced by cyclopentolate are especially prominent in children.
Feeding intolerance may follow ophthalmic use of the product in infants (see Section 4.4 Special Warnings and Precautions for Use).
A local or generalized allergic-type response to cyclopentolate consisting of an urticarial rash has been described in children.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

An ocular overdose of Cyclogyl eye drops can be flushed from the eye(s) with lukewarm water.
Excessive dosage may produce exaggerated symptoms as noted in Section 4.8 Adverse Effects (Undesirable Effects).
Systemic toxicity may occur following topical use, particularly in children. It is manifested by flushing and dryness of the skin (a rash may be present in children), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, convulsions and hallucinations and the loss of neuromuscular coordination. Severe intoxication is characterized by central nervous system depression, coma, circulatory and respiratory failure, and death. Treatment is symptomatic and supportive. In infants and small children the body surface must be kept moist.
In cases of suspected overdose the first action should be to discontinue administration of the drug. In case of severe manifestations of toxicity the antidote of choice is physostigmine salicylate.

Paediatric dose.

Slowly inject 0.5 mg physostigmine salicylate intravenously. If toxic symptoms persist and no cholinergic symptoms are produced, repeat at five minutes intervals to a maximum of 2.0 mg.

Adolescent and adult.

Slowly inject 2.0 mg physostigmine salicylate intravenously. A second dose of 1-2 mg may be given after 20 minutes if no reversal of toxic manifestations has occurred. Physostigmine salicylate can be administered subcutaneously.1,2,3
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative and paralysis of muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine.

Clinical trials.

No data are available.

5.2 Pharmacokinetic Properties

No data available.

5.3 Preclinical Safety Data

Genotoxicity.

Studies in animal or humans have not been conducted to evaluate the potential of these effects.

Carcinogenicity.

Studies in animal or humans have not been conducted to evaluate the potential of these effects.

6 Pharmaceutical Particulars

6.1 List of Excipients

Benzalkonium chloride, boric acid, disodium edetate, potassium chloride, sodium carbonate and/or hydrochloric acid (to adjust pH), purified water.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

18 months. Discard 4 weeks after opening.

6.4 Special Precautions for Storage

Store at 2 to 8°C. (Refrigerate. Do not freeze.)

6.5 Nature and Contents of Container

Cyclogyl Eye Drops are supplied in multi-dose, red LDPE bottles with natural LDPE Drop-Tainer dispensers, 15 mL.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.


Empirical formula.

C17H25NO3, HCl.

Molecular weight.

327.85.

Chemical name.

2-dimethylaminoethyl-(RS)- 2-(1-hydroxycyclopentyl)- 2-phenylacetate hydrochloride.

CAS number.

5870-29-1.

References

1. Rumack, B.H.: Anticholinergic Poisoning: Treatment with Physostigmine. Pediatrics 52(6): 499-51; 1973.
2. Duvoisin, R.C. and Katz R.: Reversal of Central Anticholinergic Syndrome in Man by Physostigmine. J.Am.Med.Assn. 206(9): 1963-65; 1968.
3. Grant W.M: Toxicology of the Eye. Second Edition, Volume 1. Springfield, Illinois, Charles C. Thomas: 1974.

7 Medicine Schedule (Poisons Standard)

Prescription Only Medicine (Schedule 4).

Summary Table of Changes